Drug intelligence / Profile preview

SPVN60

Development stage: Preclinical
Lead developer: SparingVision
Modality: Gene Therapies
Administration: Ophthalmic

Overview

SPVN60 is an ocular gene editing therapy being developed by SparingVision, in collaboration with Intellia Therapeutics, for the treatment of inherited retinal diseases. The specific molecular target of SPVN60 has not yet been disclosed publicly. As of now, its global highest R&D status is pending. The therapy represents a next-generation approach to address genetic causes of retinal degeneration[2][3].

Beyond the preview

Go deeper on SPVN60.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPVN60.

Explore the full profile